Arnaud Muller

Arnaud Muller

Auto-generated profile, based on publicly available information

Arnaud Muller

Laboratoire National de Sante

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
VGVincent Gureghian
Vincent Gureghian
HHHailee Herbst
Hailee Herbst
IKInes Kozar
Ines Kozar
KMKatarina Mihajlovic
Katarina Mihajlovic
NMNoël Malod-Dognin
Noël Malod-Dognin
SKStephanie Kreis
Stephanie Kreis
Therapy Induced Senescence (TIS) leads to sustained growth arrest of cancer cells. The associated cytostasis has been shown to be reversible and cells escaping senescence further enhance the aggressiveness of cancers. Chemicals specifically targeting senescent cells, so-called senolytics, constitute a promising avenue for improved cancer treatment in combination with targeted therapies. Understanding how cancer cells evade senescence is needed to optimise the clinical benefits of this therapeutic approach. Here we characterised the response of three different NRAS mutant melanoma cell lines to a combination of CDK4/6 and MEK inhibitors over 33 days. Transcriptomic data show that all cell lines trigger a senescence programme coupled with strong induction of interferons. Kinome profiling revealed the activation of Receptor Tyrosine Kinases (RTKs) and enriched downstream signaling of neurotrophin, ErbB and insulin pathways. Characterisation of the miRNA interactome associates miR-211-5p with resistant phenotypes. Finally, iCell-based integration of bulk and single-cell RNA-seq data identifies biological processes perturbed during senescence and predicts 90 new genes involved in its escape. Overall, our data associate insulin signaling with persistence of a senescent phenotype and suggest a new role for interferon gamma in senescence escape through the induction of EMT and the activation of ERK5 signaling.

21 June 2017 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
AAAngela Armento
Angela Armento
EIElena I. Ilina
Elena I. Ilina
TKTony Kaoma
Tony Kaoma
AMArnaud Muller
Arnaud Muller
LVLaurent Vallar
Laurent Vallar
Ulrike Naumann.Ulrike Naumann.
Ulrike Naumann.
Glioblastoma (GBM), the most frequent and aggressive malignant primary brain tumor, is characterized by a highly invasive growth. In our previous study we showed that overexpression of Carboxypeptidase E (CPE) mitigated glioma cell migration. In the present study we aimed at deciphering the regulatory mechanisms of the secreted form of CPE (sCPE). By transcriptome analysis and inhibition of signaling pathways involved in the regulation of cell growth and motility, we discovered that overexpression of sCPE was accompanied by differential regulation of mRNAs connected to the motility-associated networks, among others FAK, PAK, Cdc42, integrin, STAT3 as well as TGF-β. Especially SLUG was downregulated in sCPE-overexpressing glioma cells, paralleled by reduced expression of matrix-metalloproteinases (MMP) and, in consequence, by decreased cell migration. Expression of SLUG was regulated by ERK since inhibition of ERK reverted sCPE-mediated SLUG downregulation and enhanced cell motility. In a mouse glioma model, overexpression of sCPE significantly prolonged survival. Our results implicate a novel role for sCPE that mainly affects the expression of motility-associated genes via several signal pathways.

18 October 2022 in Allergy
Verified
Journal Article
Open access
APAurélie Poli
Aurélie Poli
AOAnaïs Oudin
Anaïs Oudin
AMArnaud Muller
Arnaud Muller
ISIlaria Salvato
Ilaria Salvato
ASAndrea Scafidi
Andrea Scafidi
MOMarkus Ollert
Markus Ollert
Background: Numerous patient‐based studies have highlighted the protective role of immunoglobulin E‐mediated allergic diseases on glioblastoma (GBM) susceptibility and prognosis. However, the mechanisms behind this observation remain elusive. Our objective was to establish a preclinical model able to recapitulate this phenomenon and investigate the role of immunity underlying such protection.Methods: An immunocompetent mouse model of allergic airway inflammation (AAI) was initiated before intracranial implantation of mouse GBM cells (GL261). RAG1‐KO mice served to assess tumor growth in a model deficient for adaptive immunity. Tumor development was monitored by MRI. Microglia were isolated for functional analyses and RNA‐sequencing. Peripheral as well as tumor‐associated immune cells were characterized by flow cytometry. The impact of allergy‐related microglial genes on patient survival was analyzed by Cox regression using publicly available datasets.Results: We found that allergy establishment in mice delayed tumor engraftment in the brain and reduced tumor growth resulting in increased mouse survival. AAI induced a transcriptional reprogramming of microglia towards a pro‐inflammatory‐like state, uncovering a microglia gene signature, which correlated with limited local immunosuppression in glioma patients. AAI increased effector memory T‐cells in the circulation as well as tumor‐infiltrating CD4+T‐cells. The survival benefit conferred by AAI was lost in mice devoid of adaptive immunity.Conclusion: Our results demonstrate that AAI limits both tumor take and progression in mice, providing a preclinical model to study the impact of allergy on GBM susceptibility and prognosis, respectively. We identify a potentiation of local and adaptive systemic immunity, suggesting a reciprocal crosstalk that orchestrates allergy‐induced immune protection against GBM.

Verified
Journal Article
Open access
SWS Wahler
S Wahler
AMA Müller
A Müller
CKC Koll
C Koll
PSP Seyed-Abbaszadeh
P Seyed-Abbaszadeh
JSJm Von Der Schulenburg
Jm Von Der Schulenburg
Background: Adjuvant treatment options have become the standard therapy for stage III and IV resectable cutaneous melanoma. Two recent studies led to the registration of dabrafenib and trametinib as targeted therapies for BRAF-mutated melanoma, and of immunotherapy with nivolumab irrespective of BRAF-mutation status. Both therapies have different spectrums of adverse events.

1 September 2026 in Research Square
Verified
Preprint
Open access
PDF file
AHAnn-Christin Hau
Ann-Christin Hau
TBTanja Buhlmann
Tanja Buhlmann
SSSophie Schreiner
Sophie Schreiner
CCCamille Cialini
Camille Cialini
VLVera Laub
Vera Laub
MMMichel Mittelbronn
Michel Mittelbronn
Glioblastoma is a highly invasive brain tumor in which diffuse infiltration into the surrounding brain parenchyma severely limits therapeutic outcome. While invasion is often described as a plastic and reversible process driven by microenvironmental cues, it remains unclear whether invasive capacity can also be maintained as stable, cell-intrinsic regulatory state. Using a serial in vitro selection approach in patient-derived glioma stem-like cultures, we identified a subpopulation with persistently increased invasive potential that was retained under non-selective conditions. Comparative transcriptomic and epigenomic profiling by RNA sequencing and genome-wide DNA methylation analysis using the EPIC array revealed coordinated transcriptional and DNA methylation remodeling associated with the invasive phenotype. Integration of transcription factor activity inference, motif enrichment analysis, and publicly available ChIP-seq chromatin datasets identified convergent invasion-associated regulatory networks and suggested altered accessibility of methylation-sensitive transcription factor binding sites. Representative methylation changes were further recapitulated across an independent panel of patient-derived glioma stem-like cultures individually classified according to their invasive capacity by transwell invasion assays, supporting the broader relevance of the identified epigenetic alterations. Functional perturbation of the transcription factor networks centered on ATF4 and MYC/MAX in established glioblastoma cell lines and patient-derived glioma stem-like cultures demonstrated their contribution to invasive behavior. Finally, invasion-associated transcriptional signatures and a 41-CpG methylation signature significantly stratified overall survival in TCGA IDH-wildtype glioblastoma patients, highlighting the clinical relevance of invasion-associated epigenetic and transcriptional remodeling. Together, these findings support a model that shapes transcription factor activity and maintains invasion-associated gene expression programs.

14 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
VGVincent Gureghian
Vincent Gureghian
HHHailee Herbst
Hailee Herbst
IKInes Kozar
Ines Kozar
KMKatarina Mihajlovic
Katarina Mihajlovic
NMNoël Malod-Dognin
Noël Malod-Dognin
SKStephanie Kreis
Stephanie Kreis
Therapy Induced Senescence (TIS) leads to sustained growth arrest of cancer cells. The associated cytostasis has been shown to be reversible and cells escaping senescence further enhance the aggressiveness of cancers. Together with targeted therapeutics, senolytics, specifically targeting senescent cancer cells, constitute a promising avenue for improved cancer treatments. Understanding how cancer cells evade senescence is needed to optimise the clinical benefits of this therapeutic approach. Here we characterised the response of three different NRAS mutant melanoma cell lines to a combination of CDK4/6 and MEK inhibitors over 33 days. Transcriptomic data show that all cell lines trigger a senescence programme coupled with strong induction of interferons. Kinome profiling revealed the activation of Receptor Tyrosine Kinases (RTKs) and enriched downstream signaling of neurotrophin, ErbB and insulin pathways. Characterisation of the miRNA interactome associates miR-211-5p with resistant phenotypes. Finally, iCELL-based integration of bulk and single-cell RNA-seq data identified biological processes perturbed during senescence, and predicts new genes involved in its escape. Overall, our data associate insulin signaling with persistence of a senescent phenotype and suggest a new role for interferon gamma in senescence escape through the induction of EMT and the activation of ERK5 signaling.